Recent developments in A2B adenosine receptor ligands

Handbook of Experimental Pharmacology

Volumn 193, Issue , 2009, Pages 99-122

  Kalla, Rao V ^a   Zablocki, Jeff ^a   Tabrizi, Mojgan Aghazadeh ^b   Baraldi, Pier Giovanni ^b  

^a CV THERAPEUTICS INC   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Adenosine receptor antagonist; Asthma; CVT 6883; LAS 38096; MRE2029F20

Indexed keywords

1 BUTYL 8 (4 CARBOXYPHENYL)XANTHINE; 1 PROPYL 8 (4 SULFOPHENYL)XANTHINE; 2 (3 FLUOROPYRIDIN 4 YL) 3,6 DI(3 PYRIDYL) 5H PYRROLO[2,3 B]PYRAZINE; 2 (3,4 DIMETHOXYPHENYL) N [5 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YL]ACETAMIDE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 AMINO 6 (2 FURYL) 3 METHYL 5 (4 PYRIDYL)PYRIMIDIN 4(3H) ONE; 4 (1,3 DIALKYL 2,4 DIOXO 2,3,4,5 TETRAHYDRO 1H PYRROLO[3,2 D]PYRIMIDIN 6 YL)BENZENESULFONAMIDE DERIVATIVE; 6 AMINO 2 (2 FURYL) 3,4' BIPYRIDINE 5 CARBONITRILE; 8 (4 CARBOXYMETHOXYPHENYL) 1,3 DIPROPYLXANTHINE; 8 (4 PYRAZOLYL)XANTHINE DERIVATIVE; 8 (5 PYRAZOLYL)XANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 PHENYLTHEOPHYLLINE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR ANTAGONIST; AMINOPYRIMIDINE DERIVATIVE; CAFFEINE; CVT 6883; DIMETHYLMALAMIDE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; LAS 38096; MRE 2028F20; MRE 2029F20; MRE 2030F20; MRS 1595; MRS 1706; N (3,4 DIMETHOXYPHENYL) 2 [5 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YLOXY]ACETAMIDE; N (4 BROMOPHENYL) 2 [4 (1,3 DIMETHYL 2,4 DIOXO 2,3,4,5 TETRAHYDRO 1H PYRROLO[3,2 D]PYRIMIDIN 6 YL)PHENOXY]ACETAMIDE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; N BENZO[1,3]DIOXOL 5 YL 2 [5 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YLOXY]ACETAMIDE; OSIP 339391; PSB 1115; PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO [1,5 C]PYRIMIDINE DERIVATIVE; PYRIMIDINE 2 (AMINO 5 PYRIMIDINYL)PYRIMIDINE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADENINE; AMINOPYRIDINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; XANTHINE DERIVATIVE;

ANGIOGENESIS; ASTHMA; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; HUMAN; INFLAMMATORY DISEASE; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG DEVELOPMENT; PHYSIOLOGY;

ADENINE; AMINOPYRIDINES; ANIMALS; ASTHMA; DRUG DISCOVERY; HUMANS; PYRAZINES; PYRIMIDINES; RECEPTOR, ADENOSINE A2B; XANTHINES;

EID: 70349306890     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-89615-9_4     Document Type: Review

References (53)

1. Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A, Filipek B, Zimmer A, M̈uller CE (2004) Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther 308:358-366
2. Aghazadeh Tabrizi M, Baraldi PG, Preti D, Romagnoli R, Saponaro G, Baraldi S, Moorman AllanR, Zaid AN, Varani, Borea PA (2008) 1,3-Dipropyl-8-(1- phenylacetamide-1H-pyrazol- 3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. Bioorg Med Chem 16:2419-2430
3. Aparici M, Nueda A, Beleta J, Prats N, Fernandez R, Miralpeix M (2006) A potent adenosine A2B receptor antagonist attenuates methacholine-induced bronchial hyperresponsiveness, mucus production and IgE levels in an allergic mouse model (Poster 162). In: CIA Symp, Malta, 5-10 May 2006
4. Baraldi PG, Cacciari B, Romagnoli R, Merighi S, Varani K, Borea PA, Spalluto G (2000) A3 adenosine receptor ligands: history and perspectives. Med Res Rev 20:103-128
5. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Varani K, Gessi S, Merighi S, Borea PA (2001) Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: a new pharmacological tool for the characterization of the human A3 adenosine receptor. Drug Dev Res 52:406-415
6. Baraldi PG, Cacciari B, Moro S, Spalluto G, Pastorin G, Da Ros T, Klotz KN, Varani K, Gessi S, Borea PA (2002) Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine derivatives as human A3 adenosine receptor antagonists. J Med Chem 45:770-780 (Pubitemid 34173930)
7. Baraldi PG, Aghazadeh Tabrizi M, Preti D, Bovero A, Romagnoli R, Fruttarolo F, Zaid AN, Moorman Allan R, Varani K, Gessi S, Merighi S, Borea PA (2004a) Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem 47: 1434-1447
8. Baraldi PG, Aghazadeh Tabrizi M, Preti D, Bovero A, Romagnoli R, Fruttarolo F, Moorman Allan R, Varani K, Borea PA (2004b) [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. Bioorg Med Chem Lett 14:3607-3610
9. Belardinelli L, Grant MB (2001) Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation. WO Patent 01060350
10. Campioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G (1998) New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 6:523-533
11. Carotti A, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Ravina E, Sanz F, Segarra V, Sotelo E, Stefanachi A, Vidal B (2006) Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor. J Med Chem 49:282-299
12. Castelhano AL, McKibben B, Steinig AG (2003) Pyrrololopyrimidine A2B selective antagonist compound, their synthesis and use. WO Patent 2003053361
13. Cushley MJ, Tattersfield AE, Holgate ST (1984) Adenosine-induced bronchoconstriction in asthma: antagonism by inhaled theophylline. Am Rev Respir Dis 129:380-384
14. Driver AG, Kukoly CA, Ali S, Mustafa SJ (1993) Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 148:91-97
15. Elzein E, Kalla R, Li X, Perry T, Parkhill E, Palle V, Varkhedkar V, Gimbel A, Zeng D, Lustig D, Leung K, Zablocki J (2006) Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol- 4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists. Bioorg Med Chem Lett 16:302-306 (Pubitemid 41680618)
16. Elzein E, Kalla RV, Li X, Perry T, Gimbel A, Zeng D, Lustig D, Leung K, Zablocki J (2008) Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. J Med Chem 51:2267-2278
17. Esteve C, Nueda A, Díaz JL, Beleta J, Ćardenas A, Lozoya E, Cadavid MI, Loza MI, Ryder H, Vidal B (2006) New pyrrolopyrimidin-6-yl benzenesulfonamides: potent A2B adenosine receptor antagonists. Bioorg Med Chem Lett 16:3642-3645
18. Feoktistov I, Wells JN, Biaggioni I (1998) Adenosine A2B receptors as therapeutic targets. Drug Dev Res 45:198-206
19. Feoktistov I, Ryzhov S, Zhong H, Goldstein AE, Matafonov A, Zeng D, Biaggioni I (2004) Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 44:649-654
20. Fozard JR, McCarth C (2002) Adenosine receptor ligands as potential therapeutics in asthma. Curr Opin Investig Drugs 3:69-77
21. Fredholm BB, IJzerman AP, Jacobson KA, Kloz K-N, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552
22. Harada H, Asano O, Hoshino Y, Yoshikawa S, Matsukura M, Kabasawa Y, Niijima J, Kotake Y, Watanabe N, Kawata T, Inoue T, Horizoe T, Yasuda N, Minami H, Nagata K, Murakami M, Nagaoka J, Kobayashi S, Tanaka I, Abe S (2001a) 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: Their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor. J Med Chem 44:170-179 (Pubitemid 32096661)
23. Harada H, Asano O, Kawata T, Inoue T, Horizoe T, Yasuda N, Nagata K, MurakamiM, Nagaoka J, Kobayashi S, Tanaka I, Abe S (2001b) 2-Alkynyl-8- aryladenines possessing an amide moiety: their synthesis and structure-activity relationships of effects on hepatic glucose production induced via agonism of the A2B adesnosine receptor. Bioorg Med Chem 9:2709-2726 (Pubitemid 32824173)
24. Harada H, Asano O, Miyazawa S, Yasuda N, Kabasawa Y, Ueda M, Yasuda M, Kotake Y (2003) Pyrimidone compounds and pharmaceutical compositions containing the same. WO 2003035640
25. Harada H, Asano O, Yasuda N, Ueda M. Yasuda M, Miyazawa S (2004) 2-Aminopyridine compounds and thereof as drugs. US Patent 6750232
26. Hayallah AM, Sandoval-Ram?rez JS, Reith U, Schobert U, Preiss B, Schumacher B, Daly JW, M*M̈uller CE (2002) 1,8-Disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J Med Chem 45:1500-1510
27. Holgate ST (2005) The Quintiles Prize Lecture 2004: the identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol 145:1009-1015
28. Jacobson KA, IJzerman AP, Linden J (1999) 1,3-Dialkylxanthie derivatives having high potency as antagonists at human A2B adenosine receptors. Drug Dev Res 47:45-53
29. Kalla R, Perry T, Elzein E, Varkhedkar V, Li X, Ibrahim P, Palle V, Xiao D, Zablocki J (2004) A2B adenosine receptor antagonists. US Patent 6,825,349
30. Kalla R, Elzein E,Marquart T, Perry T, Li X, Zablocki J (2005) A2B adenosine receptor antagonists. WO Patent 2005042534
31. Kalla R, Elzein E, Perry T, Li X, Palle V, Varkhedkar V, Gimbel A, Maa T, Zeng D, Zablocki J (2006) Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: High affinity and selective A2B sdenosine receptor antagonists. J Med Chem 49:3682-3692 (Pubitemid 43902474)
32. Kalla R, Elzein E, Perry T, Li X, Gimbel A, Yang M, Zeng D, Zablocki J (2008) Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines. Bioorg Med Chem Lett 18:1397-1401
33. Kim Y-C, Karton Y, Ji X-D, Melman N, Linden J, Jacobson KA (1999) Acyl hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptor. Drug Dev Res 47:178-188
34. Kim Y-C, Ji X-D, Melman N, Linden J, Jacobson KA (2000) Anilide derivatives of a 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J Med Chem 43:1165-1172
35. Kim S-A, Marshall MA, Melman N, Kim HS, M̈uller CE, Linden J, Jacobson KA (2002) Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 45:2131-2138
36. Kurukulasuriya R, Link JT, Madar DJ, Pei Z, Richards SJ, Rhode JJ, Souers AJ, Szczepakieicz BG (2003) Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production. Curr Med Chem 10:123-153
37. Lambertucci C, Campioni E, Costanzi G, Kachler S, Klotz KN, Volpini R, Cristalli G, Vittori S (2000) A bromine atom in C-8 position of 9-substituted adenines enhnces A2A. Drug Dev Res 50:67-74
38. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli, Zeng D (2007) Effect of a specific and selective A2B adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 320:1246-1251
39. Pastorin G, Da Ros T, Spalluto G, Deflorian F, Moro S, Cacciari B, Baraldi PG, Gessi S, Varani K, Borea PA (2003) Pyrazolo[4,3-e]-1,2,4-triazolo[1, 5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A3 and A2B adenosine receptor subtypes: a molecular modelling investigation. J Med Chem 46:4287-4296
40. Stefanachi A, Nicolotti O, Leonetti F, Cellamare S, Campagna F, Loza MI, Brea JM, Mazza F, Gavuzzo E and Carotti A (2008) 1,3-Dialkyl-8-(hetero)aryl-9- OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships. Bioorg Med Chem 16:9780-9789
41. Stewart M, Steinig AG, Ma C, Song J-P, McKibben B, Castelhano AL, MacLennan SJ (2004) [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem Pharmacol 68:305-312
42. Sun C-X, Zhong H, Mohsenin A, Morschi E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn M (2006) Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116:2173-2182
43. Vidal JB, Esteve TC (2005) Pyrimidin-2-amine derivates and their use as A2B adenosine receptor antagonists. WO Patent 2005040155
44. Vidal JB, Esteve TC, Soca PL, Eastwood PR (2007a) Pyrazine derivatives useful as adenosine receptor antagonists. WO Patent 2007017096
45. Vidal JB, Fonquerna PS, Eastwood PR, Aiguade BJ, Cardus FA, Carranco MI, Gonzalez RJ, Paredes AS (2007b) Imidazopyridine derivatives as A2B adenosine receptor antagonists. WO Patent 2007039297
46. Vidal JB, NA, Esteve TC, Domenech T, Benito S, Reinoso RF, Pont M, Calbet M, Lopez R, Cadavid MI, Loza MI, Cardenas A, Godessart N, Beleta J, Warrellow G, Ryder H (2007c) Discovery and characterization of 4-(2-furyl)-N-pyridin-3-yl- 4,5-bipyrimidin-2- amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. J Med Chem 50:2732-2736
47. Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz KN (2003) Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem 3:427-443
48. Wang G, Rieger JM, Thompson RD (2006) Pyridyl substituted xanthines. WO Patent 2006091896
49. Yan L, M̈uller CE (2004) Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. J Med Chem 47:10311043
50. Zeng D, Maa T, Wang U, Feoktistov I, Biaggioni I, Belardinelli L (2003) Expression and function of A2B adenosine receptors in the U87MG tumor cells. Drug Dev Res 58:405-411 (Pubitemid 36676341)
51. Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D (2004) A2B adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 30:118-125
52. Zhong H, Belardinelli L, Maa T, Zeng D (2005) Synergy between A2B adenosine receptors andhypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 32:2-8
53. Zhong H, Wu Y, Belardinelli L, Zeng D (2006) A2B adenosine receptors induce IL-19 from bronchial epithelial cells and results in TNF-alpha increase. Am J Respir Cell Mol Biol 35:587-592